TAKAGI Lab, IPR / Arimori

< Back

PUBLICATION LIST for T. ARIMORI Apr 2025

40. Ikeda S, Hasegawa K, Kogue Y, Arimori T, Kawamoto R, Wibowo T, Yaga M, Inada Y, Uehara H, Matsubara M, Tachikawa M, Suga M, Kida S, Shibata K, Tsutsumi K, Fukushima K, Fujita J, Ueda T, Kusakabe S, Hino A, Ichii M, Hirose A, Nakamae H, Hino M, Nakao T, Inoue M, Yoshihara K, Yoshihara S, Ueda S, Tachi T, Kuroda H, Murakami K, Kijima N, Kishima H, Igashira E, Murakami M, Takiuchi T, Kimura T, Hiroshima T, Kimura T, Shintani Y, Imai C, Yusa K, Mori R, Ogino T, Eguchi H, Takeda K, Oji Y, Kumanogoh A, Takagi J, Hosen N. (2025) CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nat. Cancer, 6(4):595-611.
39. Nishioka K, Sakai Y^#, Motooka D, Yoshikawa NI, Tojo H, Matoba S, Nagata N, Nakaya T, Arimori T^#, Hoshino A^#. (2025) Engineered DPP4 decoy confers broad-spectrum inhibition of MERS-CoV infection. Cell Biomaterials, 1(2):100018. ^#corresponding authors
38. Liu Y, Mori T, Ito Y, Kuroki K, Hayashi S, Kohda D, Shimizu T, Ishida T, Roffler SR, Kaneko MK, Kato Y, Arimori T, Teramoto T, Takemura K, Ishibashi K, Katayama Y, Maenaka K, Kakuta Y, Kitao A, Mori T. (2025) The strategy used by naïve anti-PEG antibodies to capture flexible and featureless PEG chains. Journal of Controlled Release, 380(10):396-403.
37. 有森貴夫 (2024) タンパク質立体構造の乱れを標的とするがん特異的抗HER2抗体. バイオサイエンスとインダストリー , 82(5):470-473.
36. Arimori T^#, Mihara E, Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Takagi J, Kato Y^#. (2024) Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies. Structure, 32(5):536-549 ^#corresponding authors[youtube]
35. 有森貴夫，高木淳一 (2024) 次世代型Fc融合法による超効率的な疾病関連蛋白質の生産. 実験医学, 43(2):82-88.
34. Shirai T, Nakai A, Ando E, Fujimoto J, Leach S, Arimori T, Higo D, Eerden F, Tulyeu J, Liu Y, Okuzaki D, Murayama MA, Miyata H, Nunomura K, Lin B, Tani A, Kumanogoh A, Ikawa M, Wing JB, Standley DM, Takagi J, Suzuki K. (2023) Celastrol suppresses humoral immune responses and autoimmunity by targeting the COMMD3/8 complex. Science Immunology, 8(81):eadc9324.
33. Zhang Q, Miyamoto A, Watanabe S, Arimori T, Sakai M, Tomisaki M, Kiuchi T, Takagi J, Watanabe N. (2022) Engineered fast-dissociating antibody fragments for multiplexed super-resolution microscopy. Cell Reports Methods, 2(10):100301.
32. Sugano-Nakamura N, Matoba K, Hirose M, Bashiruddin NK, Matsunaga Y, Yamashita K, Hirata K, Yamamoto M, Arimori T, Suga H, Takagi J. (2022) De novo Fc-based receptor dimerizers differentially modulate PlexinB1 function. Structure, 30(10):1411-1423.e4.
31. Arimori T, Ikemura N, Okamoto T, Takagi J, Standley DM, Hoshino A. (2022) Engineering ACE2 decoy receptors to combat viral escapability. Trends Pharmacol Sci., 43(10):838-851.
30. Ikemura N^*, Taminishi S^*, Inaba T^*, Arimori T^*, Motooka D^*, Katoh K^*, Kirita Y, Higuchi Y, Li S, Suzuki T, Itoh Y, Ozaki Y, Nakamura S, Matoba S, Standley DM, Okamoto T, Takagi J, Hoshino A. (2022) An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci Transl Med., eabn7737. ^*equally contributed
29. Arimori T, Miyazaki N, Mihara E, Takizawa M, Taniguchi Y, Cabañas C, Sekiguchi K, Takagi J. (2021) Structural mechanism of laminin recognition by integrin. Nat. Commun., 12(1):4012.
28. 星野温，有森貴夫　(2021) 指向性進化法による高親和性ACE2創出とCOVID-19創薬展開. 医学のあゆみ, 278(6):588-595.
27. 有森貴夫　(2021) タンパク質結晶化に応用可能な新規小型抗体フォーマットFv-claspの開発. 日本結晶学会誌, 63:113-120.
26. Higuchi Y^*, Suzuki T^*, Arimori T^*, Ikemura N^*, Mihara E, Kirita Y, Ohgitani E, Mazda O, Motooka D, Nakamura S, Sakai Y, Itoh Y, Sugihara F, Matsuura Y, Matoba S, Okamoto T, Takagi J, Hoshino A. (2021) Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun., 12(1):3802. ^*equally contributed
25. Kobashigawa Y, Ohara T, Morita K, Toyota Y, Nakamura T, Kotani S, Arimori T, Yamauchi S, Liu C, Kitazaki M, Wakeyama-Miyazaki Y, Suwa Y, Uchida-Kamekura M, Fukuda N, Sato T, Nakajima M, Takagi J, Yamagata Y, Morioka H. (2021) Molecular recognition of a single-chain Fv antibody specific for GA-pyridine, an advanced glycation end-product (AGE), elucidated using biophysical techniques and synthetic antigen analogues. J. Biochem., 170(3):379-387.
24. Mihara E, Watanabe S, Bashiruddin NK, Nakamura N, Matoba K, Sano Y, Maini R, Yin Y, Sakai K, Arimori T, Matsumoto K, Suga H, Takagi J. (2021) Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins. Nat. Commun., 12(1):1543.
23. Sato N, Yogo R, Yanaka S, Martel A, Porcar L, Morishima K, Inoue R, Tominaga T, Arimori T, Takagi J, Sugiyama M, Kato K. (2021) A feasibility study of inverse contrast-matching small-angle neutron scattering method combined with size exclusion chromatography using antibody interactions as model systems. J. Biochem., 169(6):701-708.
22. Wakasa A, Kaneko MK, Kato Y, Takagi J, and Arimori T. (2020) Site-specific epitope insertion into recombinant proteins using the MAP tag system. J. Biochem., 168(4):375-384.
21. Hirai H, Matoba K, Mihara E, Arimori T, and Takagi J. (2019) Crystal structure of mammalian Wnt-frizzled complex. Nat. Struct. Mol. Biol., 26(5):372-379.
20. Nakamura T, Hirata K, Fujimiya K, Chirifu M, Arimori T, Tamada T, Ikemizu S, and Yamagata Y. (2019) X-ray Structure Analysis of Human Oxidized Nucleotide Hydrolase MTH1 using Crystals Obtained under Microgravity. Int. J. Microgravity Sci. Appl., 36:360103.
19. 瀧沢士，有森貴夫，谿口征雅，高木淳一，関口清俊 (2019) ラミニン3量体の立体構造解析とインテグリンとの相互作用．生物物理, 59(2):091-093.
18. Brown ZP, Arimori T, Iwasaki K, and Takagi J. (2018) Development of a new protein labeling system to map subunits and domains of macromolecular complexes for electron microscopy. J Struct Biol., 201(3):247-251.
17. 有森貴夫，高木淳一 (2018) 小型抗体の作製技術（特集　次世代抗体医薬の衝撃）. 実験医学, 36:1849-1853.
16. 有森貴夫，高木淳一 (2018) 新規小型抗体「Fv-clasp」の開発. バイオサイエンスとバイオインダストリー, 76:132-133.
15. Saito F, Hirayasu K, Satoh T, Wang CW, Lusingu J, Arimori T, Shida K, Palacpac NMQ, Itagaki S, Iwanaga S, Takashima E, Tsuboi T, Kohyama M, Suenaga T, Colonna M, Takagi J, Lavstsen T, Horii T, and Arase H. (2017) Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature, 552(7683):101-105.
14. Sakakibara S, Arimori T, Yamashita K, Jinzai H, Motooka D, Nakamura S, Li S, Takeda K, Katayama J, El Hussien MA, Narazaki M, Tanaka T, Standley DM, Takagi J, and Kikutani H. (2017) Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. Sci. Rep., 7(1):16428.
13. Arimori T, Kitago Y, Umitsu M, Fujii Y, Asaki R, Tamura-Kawakami K, and Takagi J. (2017) Fv-clasp: An artificially designed small antibody fragment with improved production compatibility, stability, and crystallizability. Structure, 25(10):1611-1622.
12. Takizawa M^*, Arimori T^*, Taniguchi Y^*, Kitago Y, Yamashita E, Takagi J, and Sekiguchi K. (2017) Mechanistic basis for the recognition of laminin-511 by 61 integrin. Science Advances, 3(9):e1701497. ^*equally contributed
11. Waz S, Nakamura T, Hirata K, Koga-Ogawa Y, Chirifu M, Arimori T, Tamada T, Ikemizu S, Nakabeppu Y, and Yamagata Y (2017). Structural and Kinetic Studies of the Human Nudix Hydrolase MTH1 Reveal the Mechanism for Its Broad Substrate Specificity. J. Biol. Chem., 292(7):2785-2794.
10. 松永幸子，有森貴夫，高木淳一 (2017) 結晶構造から読み解く PA タグシステムの原理とタンパク質ループ構造への挿入．和光純薬時報, 85(1):2-4.
9. Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kato-Kaneko M, Kato Y, and Takagi J (2016). Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state. J. Cell Sci., 129(7):1512-1522.
8. 有森貴夫，玉田太郎 (2014). GHファミリー23に属する新奇キチナーゼの構造と機能. 日本結晶学会誌, 56:201-206.
7. Arimori T, Ito A, Nakazawa M, Ueda M, and Tamada T (2013). Crystal structure of endo-1,4-β-glucanase from Eisenia fetida. J. Synchrotron Radiat., 20(Pt 6):884-889.
6. Arimori T, Kawamoto N, Okazaki N, Nakazawa M, Miyatake K, Shinya S, Fukamizo T, Ueda M, and Tamada T (2013). Crystal structures of the catalytic domain of a novel glycohydrolase family 23 chitinase from Ralstonia sp. A-471 reveals a unique arrangement of the catalytic residues for inverting chitin hydrolysis. J. Biol. Chem., 288(26):18696-18706.
5. Arimori T, Tamaoki H, Nakamura T, Kamiya H, Ikemizu S, Takagi Y, Ishibashi T, Harashima H, Sekiguchi M, and Yamagata Y (2011). Diverse Substrate Recognition and Hydrolysis Mechanisms of Human NUDT5. Nucleic Acids Research, 39(20):8972-8983.
4. Arimori T, Yamagata Y (2011). Mechanistic insight into hydrolysis of oxidized nucleotide diphosphates by human NUDT5. Fukuoka Acta Medica, 102(11):303－312.
3. Okazaki N, Arimori T, Nakazawa M, Miyatake K, Kuroki R, Ueda M, and Tamada T (2011). Crystallization and preliminary X-ray diffraction studies of the catalytic domain of novel chitin-ase, a member of GH family 23, from the moderately thermophilic bacterium Ralstonia sp. A-471. Acta Crystallogr Sect F Struct Biol Cryst Commun., 67(Pt 4):494-497.
2. Miyata M, Sato T, Kugimiya M, Sho M, Nakamura T, Ikemizu S, Chirifu M, Mizuguchi M, Nabeshima Y, Suwa Y, Morioka H, Arimori T, Suico MA, Shuto T, Sako Y, Momohara M, Koga T, Morino-Koga S, Yamagata Y, Kai H (2010). The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry, 49(29):6104-6114.
1. Kamiya H, Hori M, Arimori T, Sekiguchi M, Yamagata Y, and Harashima H (2009). NUDT5 hydrolyzes oxidized deoxyribonucleoside diphosphates with broad substrate specificity. DNA repair, 8(10):1250-1254.

< Back